XML 45 R47.htm IDEA: XBRL DOCUMENT v2.4.1.9
Segment Information (Tables)
 12 Months Ended
Dec. 31, 2014
Segment Reporting [Abstract]  
Schedule of Financial Data for Business Segments
The financial data for the two business segments are as follows ($ amounts in thousands):
 
For the Year Ended
 
For the Year Ended
 
For the Period
 
December 31, 2014
 
December 31, 2013
 
September 29, 2012 to
December 31, 2012
January 1, 2012 to
September 28, 2012
 
(Successor)
 
(Successor)
 
(Successor)
(Predecessor)
Revenues:
 
 
 
 
 
 
Par Pharmaceutical

$1,241,131

 

$1,028,418

 

$227,312


$743,360

Par Specialty
67,490

 
69,049

 
18,827

60,508

Total revenues

$1,308,621

 

$1,097,467

 

$246,139


$803,868

 
 
 
 
 
 
 
Gross margin:
 
 
 
 
 
 
Par Pharmaceutical
436,078

 
271,396

 
33,776

296,338

Par Specialty
43,037

 
46,647

 
11,669

46,012

Total gross margin

$479,115

 

$318,043

 

$45,445


$342,350

 
 
 
 
 
 
 
Operating (loss) income:
 
 
 
 
 
 
Par Pharmaceutical
(30,938
)
 
(48,082
)
 
(25,938
)
116,591

Par Specialty
(35,674
)
 
(17,361
)
 
(3,825
)
(57,151
)
Total operating (loss) income

($66,612
)
 

($65,443
)
 

($29,763
)

$59,440

Gain on marketable securities and other investments, net
—

 
1,122

 
—

—

Gain on bargain purchase
—

 
—

 
5,500

—

Interest income
18

 
87

 
50

424

Interest expense
(108,427
)
 
(95,484
)
 
(25,985
)
(9,159
)
Loss on debt extinguishment
(3,989
)
 
(7,335
)
 
—

—

Other income
500

 
—

 
—

—

(Benefit) provision for income taxes
(72,993
)
 
(61,182
)
 
(17,653
)
29,530

Net (loss) income

($105,517
)
 

($105,871
)
 

($32,545
)

$21,175
Schedule of Total Revenues of Top Selling Products
Total revenues of our top selling products were as follows ($ amounts in thousands):

 
For the Year Ended
 
For the Year Ended
 
For the Period
Product
December 31,
2014
 
December 31,
2013
 
September 29, 2012 to
December 31, 2012
January 1, 2012 to
September 28, 2012
 
(Successor)
 
(Successor)
 
(Successor)
(Predecessor)
Par Pharmaceutical
 
 
 
 
 
 
Budesonide (Entocort® EC)

$142,853

 

$198,834

 

$36,710


$103,762

Bupropion ER (Wellbutrin®)
84,467

 
45,403

 
11,255

34,952

Propafenone (Rythmol SR®)
75,966

 
70,508

 
19,623

53,825

Amlodipine/Valsartan (Exforge®)
60,784

 
—

 
—

—

Divalproex (Depakote®)
59,052

 
46,635

 
2,436

9,099

Metoprolol succinate ER (Toprol-XL®)
46,251

 
56,670

 
31,287

154,216

Clonidine ER (Kapvay®)
45,134

 
13,008

 
—

—

Lamotrigine (Lamictal XR®)
40,673

 
54,577

 
—

—

Aplisol®
35,228

 
—

 
—

—

Modafinil (Provigil®)
2,123

 
27,688

 
16,956

88,831

Chlorpheniramine/Hydrocodone (Tussionex®)
26,899

 
33,518

 
17,403

30,706

Other (1)
594,751

 
450,148

 
83,491

249,383

Other product related revenues (2)
26,950

 
31,429

 
8,151

18,586

Total Par Pharmaceutical Revenues

$1,241,131

 

$1,028,418

 

$227,312


$743,360

 
 
 
 
 
 
 
Par Specialty
 
 
 
 
 
 
Nascobal® Nasal Spray

$32,332

 

$26,864

 

$7,138


$17,571

Megace® ES
31,653

 
39,510

 
10,910

38,322

Other and other product related revenues (2)
3,505

 
2,675

 
779

4,615

Total Par Specialty Revenues

$67,490

 

$69,049

 

$18,827


$60,508


(1)
The further detailing of revenues of the other approximately 85 generic drugs was not considered significant to the overall disclosure due to the lower volume of revenues associated with each of these generic products. No single product in the other category was significant to total generic revenues for the years ended December 31, 2014 (Successor) and December 31, 2013 (Successor), the period from September 29, 2012 to December 31, 2012 (Successor) or for the period from January 1, 2012 to September 28, 2012 (Predecessor).

(2)
Other product related revenues represents licensing and royalty related revenues from profit sharing agreements.